...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes, obesity & metabolism >Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial
【24h】

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial

机译：利拉鲁肽抑制2型糖尿病患者高脂餐后餐后甘油三酯和载脂蛋白B48升高：一项随机，双盲，安慰剂对照，交叉试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: Postprandial triglyceridaemia is a risk factor for cardiovascular disease (CVD). This study investigated the effects of steady-state liraglutide 1.8mg versus placebo on postprandial plasma lipid concentrations after 3weeks of treatment in patients with type 2 diabetes mellitus (T2DM). Methods: In a cross-over trial, patients with T2DM (n=20, 18-75years, BMI 18.5-40kg/m2) were randomized to once-daily subcutaneous liraglutide (weekly dose escalation from 0.6 to 1.8mg) and placebo. After each 3-week period, a standardized fat-rich meal was provided, and the effects of liraglutide on triglyceride (primary endpoint AUC0-8h), apolipoprotein B48, non-esterified fatty acids, glycaemic responses and gastric emptying were assessed. ClinicalTrials.gov ID: NCT00993304. Funding: Novo Nordisk A/S. Results: After 3weeks, mean postprandial triglyceride (AUC0-8h liraglutide/placebo treatment-ratio 0.72, 95% CI [0.62-0.83], p=0.0004) and apolipoprotein B48 (AUC0-8h ratio 0.65 [0.58-0.73], p0.0001) significantly decreased with liraglutide 1.8mg versus placebo, as did iAUC0-8h and Cmax (p0.001). No significant treatment differences were observed for non-esterified fatty acids. Mean postprandial glucose and glucagon AUC0-8h and Cmax were significantly reduced with liraglutide versus placebo. Postprandial gastric emptying rate [assessed by paracetamol absorption (liquid phase) and the 13C-octanoate breath test (solid phase)] displayed no treatment differences. Mean low-density lipoprotein and total cholesterol decreased significantly with liraglutide versus placebo. Conclusions: Liraglutide treatment in patients with T2DM significantly reduced postprandial excursions of triglyceride and apolipoprotein B48 after a fat-rich meal, independently of gastric emptying. Results indicate liraglutide's potential to reduce CVD risk via improvement of postprandial lipaemia.
机译：目的：餐后甘油三酸酯血症是心血管疾病（CVD）的危险因素。这项研究调查了在治疗2周后的2型糖尿病（T2DM）患者中，稳态利拉鲁肽1.8mg与安慰剂相比对餐后血浆脂质浓度的影响。方法：在一项交叉试验中，将2型糖尿病（n = 20，18-75岁，BMI 18.5-40kg / m2）患者随机分为每日一次皮下注射利拉鲁肽（每周剂量从0.6增加至1.8mg）和安慰剂。在每三周的时间后，提供标准化的高脂膳食，并评估利拉鲁肽对甘​​油三酸酯（主要终点AUC0-8h），载脂蛋白B48，非酯化脂肪酸，血糖反应和胃排空的影响。 ClinicalTrials.gov ID：NCT00993304。资金来源：Novo Nordisk A / S。结果：3周后，平均餐后甘油三酸酯（AUC0-8h利拉鲁肽/安慰剂治疗比率0.72，95％CI [0.62-0.83]，p = 0.0004）和载脂蛋白B48（AUC0-8h比率0.65 [0.58-0.73]，p <与iAUC0-8h和Cmax相比，利拉鲁肽1.8mg与安慰剂相比显着降低了0.0001（p <0.001）。对于非酯化脂肪酸，未观察到明显的治疗差异。利拉鲁肽组与安慰剂组相比，餐后平均血糖，胰高血糖素AUC0-8h和Cmax显着降低。餐后胃排空率[通过对乙酰氨基酚吸收（液相）和13C-辛酸呼气试验（固相）评估]没有治疗差异。利拉鲁肽组与安慰剂组相比，平均低密度脂蛋白和总胆固醇显着降低。结论：利拉鲁肽治疗T2DM患者可显着减少高脂餐后餐后甘油三酸酯和载脂蛋白B48的偏移，而与胃排空无关。结果表明，利拉鲁肽有可能通过改善餐后血脂来降低CVD风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号